title: Preliminary assessment of Neck Circumference in Benign Prostatic Hyperplasia in Patients with Metabolic Syndrome.
abstract: OBJECTIVE
  To investigate the impact of neck circumference (NC) in the treatment of bening prostatic hyperplasia (BPH) patients with metabolic syndrome (MtS). Additionally, we determined dose response to alpha-blockers and cut-off values for NC and waist circumference (WC), in these patients.
  
  
  METHODS
  Non-randomized, open-labelled, and multi-centre study was conducted between March 2014 and September 2015. The BPH patients were enrolled and were divided into 2 groups: with MtS (Group 1; n=94) and without MtS (Group 2; n=103). Demographic data, anthropometric measurements, blood analyses, uroflowmetric parameters, post voiding residual urine (PVR), prostate volume, quality of life (QoL) index, NC and WC were recorded. Both groups were administered oral alphablockers and response to treatment was evaluated. Receiver-operating characteristic (ROC) curves were obtained and significant p was p<0.05.
  
  
  RESULTS
  In total, 197 patients were enrolled with mean age of 60.5±8.1 years. Mean NC and WC were higher in MtS patients (p<0.001). Uroflowmetry parameters and QoL indexes were comparable between groups before treatment. International prostate symptom score, uroflowmetry parameters, and QoL significant improved in Group 2 than Group 1, at 1st and 6th months of treatment with alpha-blockers. Success rate of treatment was significant higher in Group 2 than Group 1 (p<0.001). Cut-off values were 42.5cm and 113.5cm for NC and WC respectively, for response to alpha-blockers in BPH patients with MtS.
  
  
  CONCLUSIONS
  MtS can be related with BPH and can negatively affect the response to alpha-blocker treatment. NC can be used for predicting response to alpha-blocker treatment in BPH patients with MtS.
authors.affiliation: Department of Urology, Harran University School of Medicine, Sanliurfa, Turkey.
authors.forename: Yigit
authors.initials: Y
authors.lastname: Akin
authors.affiliation: Department of Family Medicine, 14th Family Healthcare centre, Konya, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Gulmez
authors.affiliation: Department of Urology, Necip Fazil State Hospital, Kahramanmaras, Turkey.
authors.forename: Erhan
authors.initials: E
authors.lastname: Ates
authors.affiliation: Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gulum
authors.affiliation: Department of Urology, Antalya Training and Research Hospital, Antalya, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Savas
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000704:Analysis of Variance; D015992:Body Mass Index; D049628:Body Size / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000503:physiopathology*; D008875:Middle Aged; D009333:Neck / Q000033:anatomy & histology*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology*; D011788:Quality of Life; D012372:ROC Curve; D012016:Reference Values; D015203:Reproducibility of Results; D016896:Treatment Outcome; D055105:Waist Circumference / Q000502:physiology*
chemical_list: D000317:Adrenergic alpha-Antagonists; D017430:Prostate-Specific Antigen
keywords: Patients; Prostatic Hyperplasia; Quality of Life